Akura Medical, A Shifamed Portfolio Company, Welcomes Murali Srivathsa As President And Ceo

Fremont, CA: Akura Medical, a Shifamed portfolio company, appointed Murali Srivathsa as President and CEO. With over two decades of industry experience, Murali brings a wealth of medical devices and senior leadership expertise. He joins just as the team finalizes the product development of its next-generation thrombectomy device.

"I am delighted to have Murali join and lead Akura as we move closer to 510(k) filing," remarked Amr Salahieh, Founder of Shifamed and Chairman of Akura Medical. "He is an accomplished executive with an impressive record of successfully commercializing new technologies in the cardiology space, experience that will be critical as we look to disrupt the fast-growing venous thrombectomy market."

Murali most recently served as Abbott Laboratories' Divisional Vice President of Global Heart Failure Marketing, where he was responsible for key product categories such as Mechanical Circulatory Support (HeartMate), Acute Circulatory Support (CentriMag), Pulmonary Artery Pressure Monitoring (CardioMEMSTM), and Continuum – a national home medical equipment provider. Murali previously held executive leadership positions at ZOLL, Kyma Medical Technologies (acquired by ZOLL), and Corventis (acquired by Medtronic). Murali worked in various marketing and sales roles with Boston Scientific and Guidant early in his career, bringing nascent therapies to market. He has a Bachelor of Engineering in Electronics from Bangalore University in India, an Executive Masters in International Trade from the Indian Institute of Foreign Trade, and an MBA from IMD in Switzerland.

"I am excited to join the Akura team at this important time as the company prepares for these upcoming regulatory and commercial milestones," stated Murali Srivathsa, President and CEO of Akura Medical. "Despite advances in this space, VTE continues to have limited treatment options that effectively remove blood clots. Akura's easy-to-use solution aims to simplify thrombectomy by minimizing catheter exchanges and efficiently remove clots with a single-pass procedure. I look forward to working with the world-class team in bringing this novel technology to market."